-
Allergan, Inc. v. Sandoz Inc DC CAFC
- 6:11-cv-00441
- E.D. Tex.
- Judge: Michael H. Schneider +1
- Filed: 08/26/2011
- Closed: 01/13/2014
- Latest Docket Entry: 02/22/2017
- PACER
- Docket updated daily
1
Plaintiff
1
Defendant
1
Accused
Product
6
Patents-in-Suit
872
Days in
Litigation
-
Allergan, Inc. v. Sandoz Inc DC CAFC
- 6:11-cv-00441
- E.D. Tex.
- Judge: Michael H. Schneider +1
- Filed: 08/26/2011
- Closed: 01/13/2014
- Latest Docket Entry: 02/22/2017
- PACER
- Docket updated daily
Causes of Action
Infringement
Willful Patent Infringement
Market Sector
Biotech and Pharma
Assigned Judge
Previously Presiding
Leonard Davis (until 12/18/2011)
Outcome Summary
- Patent Information
-
Validity & Enforceability
Claim # | Claim Text | Outcome |
---|---|---|
2 |
A composition having a pH of about 7.3 which comprises about 0.01% bimatoprost, about 200 ppm benzalkonium chloride, citric acid monohydrate, a phosphate buffer, and NaCl wherein said composition is an aqueous liquid which is formulated for
view more
|
Enforceable and Valid (103 and 112)
Entry 303 |
Claim # | Claim Text | Outcome |
---|---|---|
1 |
A first composition administered once daily for lowering intraocular pressure in a person with glaucoma or ocular hypertension, the first composition comprising about 0.01% w/v bimatoprost and about 0.02% w/v benzalkonium chloride, wherein the first
view more
|
Enforceable and Valid (103 and 112)
Entry 303 |
7 |
A first composition administered once daily for lowering intraocular pressure in a person with glaucoma or ocular hypertension, the first composition comprising about 0.01% w/v bimatoprost and about 0.02% w/v benzalkonium chloride, wherein the first
view more
|
Enforceable and Valid (103 and 112)
Entry 303 |
8 |
The composition of claim 7 wherein the once daily administration of the first composition results in less hyperemia as compared to the once daily administration of the second composition.
|
Enforceable and Valid (103 and 112)
Entry 303 |
Claim # | Claim Text | Outcome |
---|---|---|
1 |
A method of lowering intraocular pressure in a person with glaucoma or ocular hypertension, the method comprising administering once daily to an eye of the person a first composition comprising about 0.01% w/v bimatoprost and about 0.02% w/v
view more
|
Enforceable and Valid (103 and 112)
Entry 303 |
7 |
A method of lowering intraocular pressure in a person with glaucoma or ocular hypertension, the method comprising administering once daily to an eye of the person a first composition comprising about 0.01% w/v bimatoprost and about 0.02% w/v
view more
|
Enforceable and Valid (103 and 112)
Entry 303 |
8 |
The method of claim 7 wherein the once daily administration of the first composition results in less hyperemia as compared to the once daily administration of the second composition.
|
Enforceable and Valid (103 and 112)
Entry 303 |
Claim # | Claim Text | Outcome |
---|---|---|
1 |
A method of lowering elevated intraocular pressure in a patient with open-angle glaucoma or ocular hypertension which comprises applying to the eyes of the patient an aqueous solution comprised of: about 0.01% w/v bimatoprost; about 200 ppm
view more
|
Enforceable and Valid (103 and 112)
Entry 303 |
6 |
A method of lowering intraocular pressure in a patient suffering from elevated intraocular pressure which comprises applying to the eyes of the patient an aqueous solution comprising: 0.01% w/v bimatoprost; about 200 ppm benzalkonium chloride; the
view more
|
Enforceable and Valid (103 and 112)
Entry 303 |
10 |
The method of claim 7 wherein the glaucoma is open angle glaucoma.
|
Enforceable and Valid (103 and 112)
Entry 303 |
12 |
A method of treating glaucoma in a patient comprising the following steps: applying at least once a day a formulation comprising: about 0.01% w/v bimatoprost; benzalkonium chloride in the amount of about 200 ppm; at least one buffering agent selected
view more
|
Enforceable and Valid (103 and 112)
Entry 303 |
Claim # | Claim Text | Outcome |
---|---|---|
15 |
The composition of claim 1 comprising about 0.01% w/v bimatoprost, about 0.02% w/v benzalkonium chloride, about 0.26% w/v sodium phosphate dibasic heptahydrate, about 0.014% w/v citric acid monohydrate, about 0.8% w/v sodium chloride, and water.
|
Enforceable and Valid (103 and 112)
Entry 303 |
-
Infringement
Hi-Tech Pharmacal Corporation
- 5 Details
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
Enhanced bimatoprost ophthalmic solution | US 7,851,504 B2 |
2
|
Infringement
Entry 303
|
Enhanced bimatoprost ophthalmic solution | US 8,278,353 B2 |
1, 7, 8
|
Infringement
Entry 303
|
Enhanced bimatoprost ophthalmic solution | US 8,299,118 B2 |
1, 7, 8
|
Infringement
Entry 303
|
Enhanced bimatoprost ophthalmic solution | US 8,309,605 B2 |
1, 6, 10, 12
|
Infringement
Entry 303
|
Enhanced bimatoprost ophthalmic solution | US 8,338,479 B2 |
15
|
Infringement
Entry 303
|
Lupin Limited
- 5 Details
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
Enhanced bimatoprost ophthalmic solution | US 7,851,504 B2 |
2
|
Infringement
Entry 303
|
Enhanced bimatoprost ophthalmic solution | US 8,278,353 B2 |
1, 7, 8
|
Infringement
Entry 303
|
Enhanced bimatoprost ophthalmic solution | US 8,299,118 B2 |
1, 7, 8
|
Infringement
Entry 303
|
Enhanced bimatoprost ophthalmic solution | US 8,309,605 B2 |
1, 6, 10, 12
|
Infringement
Entry 303
|
Enhanced bimatoprost ophthalmic solution | US 8,338,479 B2 |
15
|
Infringement
Entry 303
|
Lupin Pharmaceuticals Incorporated
- 5 Details
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
Enhanced bimatoprost ophthalmic solution | US 7,851,504 B2 |
2
|
Infringement
Entry 303
|
Enhanced bimatoprost ophthalmic solution | US 8,278,353 B2 |
1, 7, 8
|
Infringement
Entry 303
|
Enhanced bimatoprost ophthalmic solution | US 8,299,118 B2 |
1, 7, 8
|
Infringement
Entry 303
|
Enhanced bimatoprost ophthalmic solution | US 8,309,605 B2 |
1, 6, 10, 12
|
Infringement
Entry 303
|
Enhanced bimatoprost ophthalmic solution | US 8,338,479 B2 |
15
|
Infringement
Entry 303
|
Sandoz Inc.
- 5 Details
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
Enhanced bimatoprost ophthalmic solution | US 7,851,504 B2 |
2
|
Infringement
Entry 303
|
Enhanced bimatoprost ophthalmic solution | US 8,278,353 B2 |
1, 7, 8
|
Infringement
Entry 303
|
Enhanced bimatoprost ophthalmic solution | US 8,299,118 B2 |
1, 7, 8
|
Infringement
Entry 303
|
Enhanced bimatoprost ophthalmic solution | US 8,309,605 B2 |
1, 6, 10, 12
|
Infringement
Entry 303
|
Enhanced bimatoprost ophthalmic solution | US 8,338,479 B2 |
15
|
Infringement
Entry 303
|
Watson Laboratories, Inc. (Connecticut)
- 5 Details
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
Enhanced bimatoprost ophthalmic solution | US 7,851,504 B2 |
2
|
Infringement
Entry 303
|
Enhanced bimatoprost ophthalmic solution | US 8,278,353 B2 |
1, 7, 8
|
Infringement
Entry 303
|
Enhanced bimatoprost ophthalmic solution | US 8,299,118 B2 |
1, 7, 8
|
Infringement
Entry 303
|
Enhanced bimatoprost ophthalmic solution | US 8,309,605 B2 |
1, 6, 10, 12
|
Infringement
Entry 303
|
Enhanced bimatoprost ophthalmic solution | US 8,338,479 B2 |
15
|
Infringement
Entry 303
|
Watson Pharmaceuticals, Inc.
- 5 Details
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
Enhanced bimatoprost ophthalmic solution | US 7,851,504 B2 |
2
|
Infringement
Entry 303
|
Enhanced bimatoprost ophthalmic solution | US 8,278,353 B2 |
1, 7, 8
|
Infringement
Entry 303
|
Enhanced bimatoprost ophthalmic solution | US 8,299,118 B2 |
1, 7, 8
|
Infringement
Entry 303
|
Enhanced bimatoprost ophthalmic solution | US 8,309,605 B2 |
1, 6, 10, 12
|
Infringement
Entry 303
|
Enhanced bimatoprost ophthalmic solution | US 8,338,479 B2 |
15
|
Infringement
Entry 303
|
Watson Pharma, Inc.
- 5 Details
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
Enhanced bimatoprost ophthalmic solution | US 7,851,504 B2 |
2
|
Infringement
Entry 303
|
Enhanced bimatoprost ophthalmic solution | US 8,278,353 B2 |
1, 7, 8
|
Infringement
Entry 303
|
Enhanced bimatoprost ophthalmic solution | US 8,299,118 B2 |
1, 7, 8
|
Infringement
Entry 303
|
Enhanced bimatoprost ophthalmic solution | US 8,309,605 B2 |
1, 6, 10, 12
|
Infringement
Entry 303
|
Enhanced bimatoprost ophthalmic solution | US 8,338,479 B2 |
15
|
Infringement
Entry 303
|